ArticleClinical pharmacokinetics2023

A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.

Hironobu Tsukada et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.